This observational, descriptive, longitudinal, and prospective basket-type study (Registry #5289) prospectively evaluated the feasibility and acute toxicity of hypo-fractionated radiotherapy on the first 0.35T MR-LINAC in Spain. A total of 37 patients were included between August and December 2023, primarily with prostate tumors (59.46%), followed by pancreatic tumors (32.44%). Treatment regimens typically involved extreme hypo-fractionated radiotherapy, with precise dose delivery verified through quality assurance measures. Acute toxicity assessment at treatment completion revealed manageable cystitis, with one case persisting at the three-month follow-up. Gastrointestinal toxicity was minimal. For pancreatic tumors, daily adaptation of organ-at-risk (OAR) and gross tumor volume (GTV) was practiced, with median doses to OAR within acceptable limits. Three patients experienced gastrointestinal toxicity, mainly nausea. Overall, the study demonstrates the feasibility and safety of extreme hypo-fractionated radiotherapy on a 0.35T MR-LINAC, especially for challenging anatomical sites like prostate and pancreatic tumors. These findings support the feasibility of MR-LINAC-based radiotherapy in delivering precise treatments with minimal toxicity, highlighting its potential for optimizing cancer treatment strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11083553 | PMC |
| http://dx.doi.org/10.3390/cancers16091685 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the outcomes of MR-based versus CT-based tumor delineation in locally advanced non-small cell lung cancer treated with hypo-fractionated radiotherapy and concurrent chemotherapy.
Transl Lung Cancer Res
November 2024
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Article Synopsis
- The study compares magnetic resonance imaging (MRI) and computed tomography (CT) for tumor delineation in patients with locally advanced non-small cell lung cancer undergoing hypo-fractionated concurrent chemoradiotherapy.
- MRI provided better soft-tissue resolution, which resulted in a smaller planning target volume and fewer cases of severe toxicity compared to CT.
- There were no significant differences in locoregional progression-free survival, progression-free survival, or overall survival between the MRI-based and CT-based groups.
Comparison of online adaptive and non-adaptive magnetic resonance image-guided radiation therapy in prostate cancer using dose accumulation.
Phys Imaging Radiat Oncol
October 2024
Section for Biomedical Physics, Department of Radiation Oncology, University of Tübingen, Germany.
Article Synopsis
- Conventional image-guided radiotherapy (conv-IGRT) for prostate cancer fails to account for anatomical changes between treatment sessions, while online-adaptive magnetic resonance guided radiotherapy (OA-MRgRT) has potential for better sparing of critical organs and improved targeting.
- The study analyzed dose accumulation in ten prostate cancer patients treated with OA-MRgRT versus conv-IGRT, using advanced imaging techniques for dose mapping.
- Results showed that while both methods yielded similar target dose parameters, OA-MRgRT delivered lower doses to organs-at-risk like the rectum and bladder compared to conv-IGRT, though these differences didn't lead to clinically significant outcomes.
Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial.
Radiother Oncol
January 2025
Department of Head & Neck Oncology, All India Institute of Medical Sciences, New Delhi, India.
Purpose: Radiotherapy is frequently employed for palliative treatment in locally advanced head and neck squamous cell carcinoma (HNSCC) but radiation dose fractionation regimens are not well-defined. We designed this phase 3 randomized controlled trial to compare two weekly hypo fractionated regimes and study the effect on progression-free survival (PFS) in this subset of patients.
Materials And Methods: Non-metastatic locally advanced HNSCC patients (n = 305) who were not suitable for curative treatment were randomized to Arm A (20 Gy/5#/5 days) and Arm B (30 Gy/5#/5 days).
Geriatric determinants of curative radiotherapy scheme choice for older adults with breast cancer treatment compliance and tolerance: Results from the GERABEL study.
J Geriatr Oncol
January 2025
Department of Radiation Oncology, CHU Saint-Etienne, Saint-Etienne, France; Department of Radiation Oncology, Institut Bergonié, Bordeaux, France.
Introduction: Chronological and functional aging complicates care in older patients, and therapeutic decisions need to consider individual needs to minimise morbidity and mortality. Therapeutic decisions should be guided by a multidisciplinary geriatric assessment, allowing a complete assessment of physical and functional performance. In this context, the GERABEL study aimed to orientate the irradiation strategy based on a detailed oncogeriatric assessment in women more than 70 years old with breast cancer.
View Article and Find Full Text PDFBreast cancer radiobiology: The renaissance of whole breast radiation fractionation (Review).
Mol Clin Oncol
December 2024
Department of Radiation Oncology, King Hussein Cancer Center, Amman 11941, Jordan.
Breast cancer radiotherapy has evolved significantly, driven by decades of research into fractionation schedules aimed at optimizing treatment efficacy and minimizing toxicity. Initial trials such as NSABP B-06 and EBCTCG meta-analyses established the benefits of adjuvant whole-breast irradiation in reducing local recurrence and improving survival rates. The linear-quadratic (LQ) model provided a framework to understand tissue response to radiation, highlighting the importance of the α/β ratio in determining fractionation sensitivity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!